UC researcher urges caution using drug to treat COVID-19
Pharmaceutical scientist sees potential problems with remdesivir as a COVID-19 treatment
While the world has its eyes on vaccines to stop the spread of coronavirus, therapeutics are still necessary to treat hospitalized patients. One of these treatments, remdesivir, is the first and only antiviral agent of its kind that the U.S. Food and Drug Administration (FDA) has approved so far for COVID-19.
Research at the University of Cincinnati, however, contends that this antiviral drug is being used too indiscriminately when treating patients hospitalized with the virus. The study is published in the journal Fundamental & Clinical Pharmacology.
The FDA approved remdesivir, marketed as Veklury, for emergency use authorization in May 2020 to treat COVID-19 and granted full approval for treatment in October 2020. The World Health Organization came out in November 2020 with a conditional recommendation advising against its use entirely citing: “More research is needed, especially to provide higher certainty of evidence for specific groups of patients.”
In the UC study, lead author Bingfang Yan, a pharmaceutical scientist, and his UC graduate students Yue Shen and William Eades, found that the drug permanently stops the activity of an enzyme called CES-2, which is found in the intestine, liver and kidney and is needed for the breakdown of many medications.
“This enzyme normally breaks down and activates medicines in certain antivirals or inactivates other medicines such as in certain anticoagulants,” says Yan, professor at the James L. Winkle College of Pharmacy. On the other hand, he says this breakdown increases the toxicity of many more medications such as with heart medicines and anticancer drugs.
An antiviral is a drug that fights viruses, and an anticoagulant is a drug that hinders the clotting of blood.
What further complicates the issue, Yan says, is that when delivered through an IV, remdesivir does not treat the virus unless the body has additional specific enzymes, which are not found in all patients. It can also cause other antiviral drugs, such as those used for HIV/AIDs and hepatitis C, to not work properly.
Remdesivir is only administered through the veins in a hospital setting, and the FDA typically recommends a dose of once a day, for approximately 10 days. “intravenous injection of remdesivir can cause safety concerns because of high initial concentrations of the drug in the system,” says Yan, noting, “If physicians use it, they have to use it with caution.
"Clearly, the treatment should be used for the right patients and in the proper dosages with care when used in combination with other medications.”
Yan’s UC laboratory studies how drugs are metabolized in the body to see if certain people should or should not use the drug or use it at a different dose. He has, for decades, been supported by the National Institutes of Health.
Photo at top is the exterior of the James L. Winkle College of Pharmacy. Photo/Colleen Kelley/UC Creative + Brand
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
UC garners sustainable, green campus success
April 19, 2021
University of Cincinnati Gold LEED certifications, student-involved energy-efficient programs and climate-friendly green technologies elevate UC to a national award-winning sustainable campus.
Huff Post: The best workouts to do if you had COVID-19
April 16, 2021
UC Health orthopedic surgeon Brian Grawe, MD, advises on when it's safe to exercise if you catch COVID-19.
Yahoo: Researchers find a new treatment for rare muscular disease
April 16, 2021
University of Cincinnati researchers have found a newer, more effective treatment for the disease Pompe that could become the new standard of care for the rare condition.